RHYTHM PHARMACEUTICALS, INC. Increase (Decrease) in Other Noncurrent Assets
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Increase (Decrease) in Other Noncurrent Assets of -$435.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was $0.00.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was -$435.00K.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was $681.00K.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $5.24M.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for fiscal 2025 was $397.00K.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for fiscal 2024 was -$7.94M.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for fiscal 2023 was -$1.66M, a 134.21% decline from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for fiscal 2022 was $4.84M, a 59.04% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$435.00K 10-Q · filed 2026-08-04 | $246.00K derived: sum of 3 quarters · filed 2026-08-04 | $5.49M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$435.00K 10-Q · filed 2026-05-05 | $246.00K derived: sum of 2 quarters · filed 2026-05-05 | $5.49M derived: sum of 3 quarters · filed 2026-05-05 | $64.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $681.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.92M derived: sum of 2 quarters · filed 2026-02-26 | $499.00K derived: sum of 3 quarters · filed 2026-08-04 | $397.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $5.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$182.00K derived: sum of 2 quarters · filed 2026-08-04 | -$284.00K 10-Q · filed 2025-11-04 | -$5.07M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$5.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$5.53M 10-Q · filed 2026-08-04 | -$10.31M derived: sum of 3 quarters · filed 2026-08-04 | -$11.22M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$102.00K 10-Q · filed 2026-05-05 | -$4.89M derived: sum of 2 quarters · filed 2026-05-05 | -$5.80M derived: sum of 3 quarters · filed 2026-05-05 | -$6.85M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$4.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$5.69M derived: sum of 2 quarters · filed 2026-02-26 | -$6.75M derived: sum of 3 quarters · filed 2026-02-26 | -$7.94M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$908.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$1.96M derived: sum of 2 quarters · filed 2025-11-04 | -$3.16M 10-Q · filed 2025-11-04 | -$3.15M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$2.25M 10-Q · filed 2025-08-05 | -$2.25M derived: sum of 3 quarters · filed 2026-02-26 | -$2.78M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$1.20M 10-Q · filed 2025-05-07 | -$1.19M derived: sum of 2 quarters · filed 2026-02-26 | -$1.73M derived: sum of 3 quarters · filed 2026-02-26 | -$2.95M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$533.00K derived: sum of 2 quarters · filed 2026-02-26 | -$1.75M derived: sum of 3 quarters · filed 2026-02-26 | -$1.66M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$537.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.76M derived: sum of 2 quarters · filed 2024-11-06 | -$1.66M 10-Q · filed 2024-11-06 | -$1.66M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | -$1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$1.12M 10-Q · filed 2024-08-06 | -$1.12M derived: sum of 3 quarters · filed 2025-02-28 | -$254.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $99.00K 10-Q · filed 2024-05-07 | $98.00K derived: sum of 2 quarters · filed 2025-02-28 | $968.00K derived: sum of 3 quarters · filed 2025-02-28 | -$1.72M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $869.00K derived: sum of 2 quarters · filed 2025-02-28 | -$1.82M derived: sum of 3 quarters · filed 2025-02-28 | $4.84M 10-K · filed 2025-02-28 |
| 2022-09-30 | $870.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$1.82M derived: sum of 2 quarters · filed 2023-11-08 | $4.84M 10-Q · filed 2023-11-08 | $6.12M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $3.97M 10-Q · filed 2023-08-01 | $5.25M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2022-03-31 | $6.66M 10-Q · filed 2023-05-02 | $7.94M derived: sum of 2 quarters · filed 2024-02-29 | ||
| 2021-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $11.81M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $10.53M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |